Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 82

1.

Neurological safety of fingolimod: An updated review.

Yoshii F, Moriya Y, Ohnuki T, Ryo M, Takahashi W.

Clin Exp Neuroimmunol. 2017 Aug;8(3):233-243. doi: 10.1111/cen3.12397. Epub 2017 Jun 18. Review.

2.

The role of natalizumab in the treatment of multiple sclerosis: benefits and risks.

Singer BA.

Ther Adv Neurol Disord. 2017 Sep;10(9):327-336. doi: 10.1177/1756285617716002. Epub 2017 Jun 23. Review.

3.

HIV-1 Associated Opportunistic Infections, Toxoplasmosis.

Ayoade F, Joel Chandranesan AS.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2017 Jun-.
2017 Oct 13.

4.

Visual consequences of medications for multiple sclerosis: the good, the bad, the ugly, and the unknown.

Moss HE.

Eye Brain. 2017 Jun 29;9:13-21. doi: 10.2147/EB.S140481. eCollection 2017. Review.

5.

The use of natalizumab for multiple sclerosis.

Brandstadter R, Katz Sand I.

Neuropsychiatr Dis Treat. 2017 Jun 28;13:1691-1702. doi: 10.2147/NDT.S114636. eCollection 2017. Review.

6.

Immune Reconstitution Inflammatory Syndrome Unmasking or Worsening AIDS-Related Progressive Multifocal Leukoencephalopathy: A Literature Review.

Fournier A, Martin-Blondel G, Lechapt-Zalcman E, Dina J, Kazemi A, Verdon R, Mortier E, de La Blanchardière A.

Front Immunol. 2017 May 23;8:577. doi: 10.3389/fimmu.2017.00577. eCollection 2017. Review.

7.

Natalizumab in Multiple Sclerosis: Long-Term Management.

Clerico M, Artusi CA, Liberto AD, Rolla S, Bardina V, Barbero P, Mercanti SF, Durelli L.

Int J Mol Sci. 2017 Apr 29;18(5). pii: E940. doi: 10.3390/ijms18050940. Review.

8.

Review on the role of the human Polyomavirus JC in the development of tumors.

Delbue S, Comar M, Ferrante P.

Infect Agent Cancer. 2017 Feb 3;12:10. doi: 10.1186/s13027-017-0122-0. eCollection 2017. Review.

9.

In Vitro and In Vivo Models for the Study of Human Polyomavirus Infection.

Barth H, Solis M, Kack-Kack W, Soulier E, Velay A, Fafi-Kremer S.

Viruses. 2016 Oct 22;8(10). pii: E292. Review.

10.

Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope.

Kizhedath A, Wilkinson S, Glassey J.

Arch Toxicol. 2017 Apr;91(4):1595-1612. doi: 10.1007/s00204-016-1876-7. Epub 2016 Oct 20. Review.

11.

Rituximab for Rheumatoid Arthritis.

Cohen MD, Keystone E.

Rheumatol Ther. 2015 Dec;2(2):99-111. Epub 2015 Aug 19. Review.

12.

Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy.

Linker RA, Haghikia A.

Ther Adv Chronic Dis. 2016 Jul;7(4):198-207. doi: 10.1177/2040622316653307. Epub 2016 Jun 10. Review.

13.

Clinical Trials in Neurovirology: Successes, Challenges, and Pitfalls.

Haubenberger D, Clifford DB.

Neurotherapeutics. 2016 Jul;13(3):571-81. doi: 10.1007/s13311-016-0440-8. Review.

14.

Gene Editing for Treatment of Neurological Infections.

White MK, Kaminski R, Wollebo H, Hu W, Malcolm T, Khalili K.

Neurotherapeutics. 2016 Jul;13(3):547-54. doi: 10.1007/s13311-016-0439-1. Review.

15.

Use of interleukin-2 for management of natalizumab-associated progressive multifocal leukoencephalopathy: case report and review of literature.

Dubey D, Zhang Y, Graves D, DeSena AD, Frohman E, Greenberg B.

Ther Adv Neurol Disord. 2016 May;9(3):211-5. doi: 10.1177/1756285615621029. Epub 2015 Dec 17. Review.

16.

Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations.

Prosperini L, Pontecorvo S.

Ther Clin Risk Manag. 2016 Mar 2;12:339-50. doi: 10.2147/TCRM.S85099. eCollection 2016. Review.

17.

Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations.

Ayzenberg I, Hoepner R, Kleiter I.

Ther Clin Risk Manag. 2016 Feb 19;12:261-72. doi: 10.2147/TCRM.S65558. eCollection 2016. Review.

18.

Investigation of Molecular Mechanism of JC virus Viroporin Activity.

Suzuki T.

Uirusu. 2015;65(1):135-44. doi: 10.2222/jsv.65.135. Review. Japanese.

19.

Progressive Multifocal Leukoencephalopathy.

Adang L, Berger J.

F1000Res. 2015 Dec 10;4. pii: F1000 Faculty Rev-1424. doi: 10.12688/f1000research.7071.1. eCollection 2015. Review.

20.

The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects.

Sorensen PS, Blinkenberg M.

Ther Adv Neurol Disord. 2016 Jan;9(1):44-52. doi: 10.1177/1756285615601933. Review.

Supplemental Content

Loading ...
Support Center